Epilepsy
Conditions
Interventions
PET scans will be performed on patients with epilepsy after administration of the PET tracer [11C]OCS5.
Sponsors
Yamasue Hidenori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Individuals scheduled to undergo surgery for epilepsy (2) Individuals with no history of neurosurgery on the same side of the brain due to epilepsy (3) Men and women aged 18 years or older but under 55 years at the time of obtaining consent (4) Individuals who have provided written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Contraindications to MRI (2) Significant structural brain abnormalities (3) Pregnant women, breastfeeding women, or women who may be pregnant (4) History of hypersensitivity to oxytocin (5) History of head trauma accompanied by loss of consciousness lasting 5 minutes or longer (6) History of alcohol-related disorders or other substance-related disorders (7) Individuals with serious comorbid conditions (8) Individuals with severe allergies (e.g., anaphylaxis) or specific constitutional conditions (9) Individuals unable to use contraception for 2 days before and after administration of the study drug (10) Individuals who have participated in another PET study (involving radiation exposure) within 1 year prior to obtaining informed consent (11) Any other individuals deemed ineligible for this study by the principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between brain distribution following administration of the OXTR-PET tracer [11C]OCS5 and receptor levels of OXTR and AVPR in excised tissues as determined by in vitro ARG | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of the OXTR-PET tracer [11C]OCS5 | — |
Contacts
Public ContactMasamichi Yokokura
Hamamatsu University School of Medicine
Outcome results
None listed